

Press Release

15 June 2023 08:30:00 CEST

2cureX Newsletter. Our colorectal cancer portfolio is on track - Pancreatic cancer is next.

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, has today issued a newsletter that can be accessed via the attachment with this message.

We regularly publish such newsletters compiling recent events and news that can be of interest to our subscribers and followers.

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB

Attachments

[2cureX Newsletter June 2023](#)

[2cureX Newsletter. Our colorectal cancer portfolio is on track - Pancreatic cancer is next.](#)